Preventive treatment is often insufficient for patients with chronic migraine. In 2023, eptinezumab – an intravenous CGRP inhibitor – was approved in Norway for patients who have failed at least five other preventive drugs and two subcutaneous CGRP inhibitors.
This project is a retrospective observational study investigating the efficacy and tolerability of eptinezumab in a Norwegian hospital population with extensive treatment failure, a patient group often excluded from international real-world studies. The goal is to provide knowledge that can improve treatment options for the most severely affected migraine patients.
The project is led by postdoctoral fellow Andrej Khanevski.
Read more : https://app.cristin.no/projects/show.jsf?id=2736545